Skip to main content
. 2021 Oct 8;6(19):e145172. doi: 10.1172/jci.insight.145172

Figure 2. PRR11 knockdown inhibited ccRCC cell proliferation.

Figure 2

(A–D) MTT assay was used to evaluate the proliferation and viability of PRR11 knockdown and PRR11-overexpressing ccRCC cells (n = 3). (E–H) A clonogenic assay was used to estimate the colony formation ability of PRR11 knockdown and PRR11-overexpressing ccRCC cells, and the clone numbers were statistically analyzed (n = 3). The data are shown as mean ± SD. One-way ANOVA with Dunnett’s multiple comparisons test (A, C, and F) and 2-tailed t test (B, D, and H) analyses were performed. *P < 0.05, **P < 0.01, ***P < 0.001. PRR11, proline rich 11; ccRCC, clear cell renal cell carcinoma.